WO2004014426A1 - Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer - Google Patents

Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer Download PDF

Info

Publication number
WO2004014426A1
WO2004014426A1 PCT/GB2003/003390 GB0303390W WO2004014426A1 WO 2004014426 A1 WO2004014426 A1 WO 2004014426A1 GB 0303390 W GB0303390 W GB 0303390W WO 2004014426 A1 WO2004014426 A1 WO 2004014426A1
Authority
WO
WIPO (PCT)
Prior art keywords
acceptable salt
cancer
effective amount
human
treatment
Prior art date
Application number
PCT/GB2003/003390
Other languages
French (fr)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002495489A priority Critical patent/CA2495489A1/en
Priority to BR0313117-3A priority patent/BR0313117A/en
Priority to EP03784248A priority patent/EP1534338A1/en
Priority to NZ537754A priority patent/NZ537754A/en
Priority to AU2003252976A priority patent/AU2003252976B2/en
Priority to JP2004527018A priority patent/JP2006500346A/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to US10/523,838 priority patent/US20050245549A1/en
Priority to MXPA05001457A priority patent/MXPA05001457A/en
Publication of WO2004014426A1 publication Critical patent/WO2004014426A1/en
Priority to NO20050528A priority patent/NO20050528L/en
Priority to IL16662505A priority patent/IL166625A0/en
Priority to US12/501,593 priority patent/US20100130493A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with ZD 1839; to a pharmaceutical composition comprising ZD6474 and ZD1839; to a combination product comprising ZD6474 and ZD1839 for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and ZD1839; to the use of ZD6474 and ZD1839 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warmblooded animal such as a human which is optionally being treated with ionising radiation.
  • Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function.
  • Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1 : 27-31).
  • vascular permeability is thought to play a role in both normal and pathological physiological processes (CuBinan-Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324).
  • Several polypeptides with in vitro endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (NEGF).
  • aFGF & bFGF acidic and basic fibroblast growth factors
  • NEGF vascular endothelial growth factor
  • NEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al, 1995, Breast Cancer Research and Treatment, 36:139-155) and vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264: 20017-20024).
  • Antagonism of NEGF action by sequestration of NEGF with antibody can result in inhibition of tumour growth (Kim et al, 1993, Nature 362: 841-844).
  • Receptor tyrosine kinases are important in the transmission of biochemical signals across the plasma membrane of cells.
  • transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, at least nineteen distinct RTK subfamilies, defined by amino acid sequence homology, have been identified.
  • ZD1839 is N-(3-cHoro-4-fluorophenyl)-7-methoxy-6-(3- mo hol opropoxy)quinazolm-4-amine:
  • ZD1839 ZD1839 is also known as gefitinib and is also known as IressaTM (Trademark of AstraZeneca UK Limited) and it is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
  • ZD1839 is described in International Patent Application Publication No. WO 96/33980.
  • EGER epidermal growth factor receptor
  • EGFR is a member of the erbB family of receptor tyrosine kinases, which includes EGFR, erbB2, erbB3 and erbB4, and it is known that these receptor tyrosine kinases are frequently involved in driving the proliferation and survival of tumour cells (reviewed in Olayioye et al., EMBO J., 2000, 19, 3159).
  • One mechanism by which this can be accomplished is by overexpression of the receptor at the protein level, generally as a result of gene amplification. This has been observed in many common human cancers (reviewed in Klapper et al., Adv. Cancer Res., 2000, 77, 25), such as breast cancer (Sainsbury et al., Brit. J.
  • NSCLCs non-small cell lung cancers
  • adenocarcinomas Cerny et al., Brit. J. Cancer, 1986, 54, 265; Reubi et al., Int. J.
  • erbB type receptor tyrosine kinase family may be implicated in a number of non-malignant proliferative disorders because amplification and/or activity of erbB receptor tyrosine kinases has been detected in psoriasis (Ben-Bassat, Curr. Pharm Des., 2000, 6, 933; Elder et al., Science, 1989, 243, 811), benign pro static hyperplasia (BPH) (Kumar et al., Int. Urol. Nephrol., 2000, 32,73), atherosclerosis and restenosis (Bokemeyer et al., Kidney Int., 2000, 58, 549). It is therefore expected that inhibitors of erbB type receptor tyrosine kinases will be useful in the treatment of these and other non-malignant disorders involving excessive cellular proliferation.
  • ZD1839 possesses EGF RTK inhibitory activity (J R Woodburn et al in Proc. Amer. Assoc. Cane. Res., 1997, 38, 633 and Pharmacol. Ther., 1999, 82, 241-250) and is an inhibitor of the proliferation of cancer tissue. It is stated in WO 96/33980 that compounds of the invention, which include ZD1839, may be given conjointly with other cancer therapies.
  • the anti-proliferative treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the quinazoline derivative of the invention, one or more other anti-tumour substances, for example cytotoxic or cytostatic anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine, vindesine and vinorelbine; tubulin disassembly inhibitors such as taxol; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; antimetabolites, for example 5-fluorouracil, tegafur, methotrexate, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European Patent Application No.
  • cytotoxic or cytostatic anti-tumour substances for example those selected from, for example, mitotic inhibitors, for example vinblastine, vindesine and vinorelbine
  • tubulin disassembly inhibitors
  • antibiotics for example adriamycin, mitomycin and bleomycin
  • enzymes for example asparaginase
  • topoisomerase inhibitors for example etoposide and camptothecin
  • biological response modifiers for example interferon
  • anti-hormones for example antioestrogens such as tamoxifen, for example antiandrogens such as 4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)- propionanilide or, for example LHRH antagonists or LHRH agonists such as goserelin, leuprorelin or buserelin and hormone synthesis inhibitor
  • 0296749 for example 2,2'-[5-(lH- 1,2,4- triazol-l-ylmethyl)-l,3-phenylene]bis(2-methylpropionitrile), and, for example, inhibitors of 5 -reductase such as 17 ⁇ -(N-tert-butylcarbamoyl)-4-aza-5 ⁇ -androst-l-en-3-one.”
  • Anti-cancer effects of a method of treatment of the present invention include, but are not limited to, anti-tumour effects, the response rate, the time to disease progression and the survival rate.
  • Anti-tumour effects of a method of treatment of the present invention include but are not limited to, inhibition of tumour growth, tumour growth delay, regression of tumour, shrinkage of tumour, increased time to regrowth of tumour on cessation of treatment, slowing of disease progression.
  • a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof.
  • a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof.
  • a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal which comprises adrninistering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof.
  • a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warmblooded animal such as a human which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof; wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
  • a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof; wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
  • a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof; wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
  • a pharmaceutical composition wliich comprises ZD6474 or a pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.
  • a combination product comprising ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof, for use in a method of treatment of a human or a mal body by therapy.
  • a kit comprising ZD6474 or a pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt thereof.
  • kits comprising: a) ZD6474 or a pharmaceutically acceptable salt thereof in a first unit dosage form; b) ZD1839 or a pharmaceutically acceptable salt thereof in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • a kit comprising: a) ZD6474 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient or carrier, in a first unit dosage form; b) ZD1839 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient or carrier, in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • ZD6474 or a pharmaceutically acceptable salt thereof and ZD 1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.
  • ZD6474 or a pharmaceutically acceptable salt thereof and ZD 1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti- cancer effect in a warm-blooded animal such as a human.
  • a therapeutic combination treatment comprising the administration of an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable excipient or carrier, and the simultaneous, sequential or separate administration of an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof; wherein ZD1839 may optionally be administered together with a pharmaceutically acceptable excipient or carrier, to a warm-blooded ar ⁇ nal such as a human in need of such therapeutic treatment.
  • Such therapeutic treatment includes an antiangiogenic and/or vascular permeability effect, an anti-cancer effect and an anti-tumour effect.
  • a combination treatment of the present invention as defined herein may be achieved by way of the simultaneous, sequential or separate administration of the individual components of said treatment.
  • a combination treatment as defined herein may be applied as a sole therapy or may involve surgery or radiotherapy or an additional chemotherapeutic agent, in addition to a combination treatment of the invention.
  • Surgery may comprise the step of partial or complete tumour resection, prior to, during or after the administration of the combination treatment with ZD6474 described herein.
  • Other chemotherapeutic agents for optional use with a combination treatment of the present invention include those described in WO 01/32651 which is incorporated herein by reference. Such chemotherapy may cover five main categories of therapeutic agent:
  • biological response modifiers for example interferon
  • antibodies for example edrecolomab
  • the administration of a triple combination of ZD6474, ZD 1839 and ionising radiation may produce effects, such as anti-tumour effects, greater than those achieved with any of ZD6474, ZD1839 and ionising radiation used alone, greater than those achieved with the combination of ZD6474 and ZD1839, greater than those achieved with the combination of ZD6474 and ionising radiation and greater than those achieved with the combination of ZD1839 and ionising radiation.
  • a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
  • a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
  • a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
  • a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm- blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation, wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
  • a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation, wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
  • a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation, wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
  • ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
  • ZD6474 or a pharmaceutically acceptable salt thereof and ZD 1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti- tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
  • a therapeutic combination treatment comprising the administration of an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable excipient or carrier, and the administration of an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable excipient or carrier and the administration of an effective amount of ionising radiation, to a warm-blooded animal such as a human in need of such therapeutic treatment wherein the ZD6474, ZD1839 and ionising radiation may be administered simultaneously, sequentially or separately and in any order.
  • a warm-blooded animal such as a human which is being treated with ionising radiation means a warm-blooded animal such as a human which is treated with ionising radiation before, after or at the same time as the administration of a medicament or combination treatment comprising ZD6474 and ZD1839.
  • said ionising radiation may be given to said warm-blooded animal such as a human within the period of a week before to a week after the administration of a medicament or combination treatment comprising ZD6474 and ZD1839.
  • ZD6474, ZD1839 and ionising radiation may be administered separately or sequentially in any order, or may be administered simultaneously.
  • the warm-blooded animal may experience the effect of each of ZD6474, ZD1839 and radiation simultaneously.
  • the ionising radiation is administered before one of ZD6474 and ZD1839 or after one of ZD6474 and ZD1839.
  • the ionising radiation is administered before both ZD6474 and ZD1839 or after both ZD6474 and ZD1839.
  • ZD6474 is administered to a warmblooded animal after the animal has been treated with ionising radiation.
  • ZD6474 and ZD1839 are dosed daily continuously for a longer period of time during which time ionising radiation is administered periodically, that is for a few days, for example 1, 2, 3, 4 or 5 days at a time.
  • the effect of a method of treatment of the present invention is expected to be at least equivalent to the addition of the effects of each of the components of said treatment used alone, that is, of each of ZD6474 and ZD1839 or of each of ZD6474, ZD1839 and ionising radiation used alone.
  • the effect of a method of treatment of the present invention is expected to be greater than the addition of the effects of each of the components of said treatment used alone, that is, of each of ZD6474 and ZD 1839 or of each of ZD6474, ZD1839 and ionising radiation, used alone.
  • the effect of a method of treatment of the present invention is expected to be a synergistic effect.
  • a combination treatment is defined as affording a synergistic effect if the effect is therapeutically superior, as measured by, for example, the extent of the response, the response rate, the time to disease progression or the survival period, to that achievable on dosing one or other of the components of the combination treatment at its conventional dose.
  • the effect of the combination treatment is synergistic if the effect is therapeutically superior to the effect achievable with ZD6474 or ZD1839 or ionising radiation alone.
  • the effect of the combination treatment is synergistic if a beneficial effect is obtained in a group of patients that does not respond (or responds poorly) to ZD6474 or ZD1839 or ionising radiation alone.
  • synergy is deemed to be present if the conventional dose of ZD6474 or ZD1839 or ionising radiation may be reduced without detriment to one or more of the extent of the response, the response rate, the time to disease progression and survival data, in particular without detriment to the duration of the response, but with fewer and/or less troublesome side-effects than those that occur when conventional doses of each component are used.
  • Combination treatments of the invention are of interest for their antiangiogenic and/or vascular permeability effects.
  • Combination treatments of the invention are expected to be useful in the prophylaxis and treatment of a wide range of disease states where inappropriate angiogenesis occurs including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, lymphoedema, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation including macular degeneration.
  • combination treatments of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More especially combination treatments of the present invention are expected to slow advantageously the growth of tumours in lung cancer, particularly non- small cell lung cancer (NSCLC).
  • NSCLC non- small cell lung cancer
  • combination treatments of the invention are expected to inhibit any form of cancer associated with NEGF including leukaemia, mulitple myeloma and lymphoma and also, for example, to inhibit the growth of those primary and recurrent solid tumours wliich are associated with NEGF, especially those tumours which are significantly dependent on NEGF for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin, particularly ⁇ SCLC.
  • ZD6474 and ZD1839 are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with EGF especially those tumours which are significantly dependent on EGF for their growth and spread.
  • ZD6474 and ZD1839 optionally with ionising radiation, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with both NEGF and EGF especially those tumours which are significantly dependent on NEGF and EGF for their growth and spread.
  • compositions described herein may be in a form suitable for oral administration, for example as a tablet or capsule, for nasal administration or administration by inhalation, for example as a powder or solution, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream, for rectal administration for example as a suppository or the route of administration may be by direct injection into the tumour or by regional delivery or by local delivery.
  • parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
  • sterile solution for example as a sterile solution, suspension or emulsion
  • topical administration for example as an ointment or cream
  • rectal administration for example as a suppository or the route of administration may be by direct injection into the tumour or by regional delivery or by local delivery.
  • the ZD6474 of the combination treatment may be delivered endoscopicaUy, intratracheaUy, intralesionaUy, percutaneously, intravenously, subcutaneously, intraperitoneaUy or intratumouraUy.
  • ZD6474 is administered oraUy.
  • the compositions described herein may be prepared in a conventional manner using conventional excipients.
  • the compositions of the present invention are advantageously presented in unit dosage form.
  • ZD6474 wh normally be administered to a warm-blooded animal at a unit dose within the range 10-500mg per square metre body area of the animal, for example approximately 0.3- 15mg/kg in a human.
  • a unit dosage form such as a tablet or capsule wiU usuaUy contain, for example 25-500mg of active ingredient.
  • a daUy dose in the range of 0.5-5mg/kg is employed.
  • a conventional tablet formulation may be used for oral administration to humans containing 50 mg, 100 mg, 250 mg or 500 mg of active ingredient.
  • the daUy oral dose of ZD 1839 is, for example, in the range 25 to 750 mg, preferably in the range 50 to 600 mg, more preferably in the range 100 to 400mg.
  • Radiotherapy may be administered according to the known practices in clinical radiotherapy.
  • the dosages of ionising radiation wiU be those known for use in clinical radiotherapy.
  • the radiation therapy used wiU include for example the use of ⁇ -rays, X-rays, and/or the directed dehvery of radiation from radioisotopes.
  • Other forms of DNA damaging factors are also included in the present invention such as microwaves and UV-irradiation.
  • X-rays may be dosed in daily doses of 1.8-2.0Gy, 5 days a week for 5-6 weeks. NormaUy a total fractionated dose will he in the range 45-60Gy.
  • Single larger doses, for example 5-10Gy may be administered as part of a course of radiotherapy. Single doses may be administered intraoperatively.
  • Hyperfractionated radiotherapy may be used whereby small doses of X-rays are administered regularly over a period of time, for example O.lGy per hour over a number of days. Dosage ranges for radioisotopes vary widely, and depend on the half- life of the isotope, the strength and type of radiation emitted, and on the uptake by ceUs.
  • the size of the dose of each therapy which is required for the therapeutic or prophylactic treatment of a particular disease state wiU necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. For example, it may be necessary or desirable to reduce the above-mentioned doses of the components of the combination treatments in order to reduce toxicity.
  • the present invention relates to combinations of ZD 1839 or a salt thereof with ZD6474 or with a salt of ZD6474.
  • Salts of ZD 1839 for use in pharmaceutical compositions wiU be pharmaceuticaUy acceptable salts, but other salts may be useful in the production of ZD 1839 and its pharmaceuticaUy acceptable salts.
  • Salts include, for example, an acid-addition salt of ZD1839, for example, a mono- or di-acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric, maleic, tartaric, furnaric, methanesulphonic or 4-toluenesulphonic acid.
  • an inorganic or organic acid for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric, maleic, tartaric, furnaric, methanesulphonic or 4-toluenesulphonic acid.
  • Salts of ZD6474 for use in pharmaceutical compositions wiU be pharmaceuticaUy acceptable salts, but other salts may be useful in the production of ZD6474 and its pharmaceuticaUy acceptable salts.
  • Such salts may be formed with an inorganic or organic base which affords a pharmaceuticaUy acceptable cation.
  • Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2- hydroxyethyl) amine.
  • ZD6474 may be synthesised according to any of the known processes for making ZD6474.
  • ZD6474 may be made according to any of the processes described in WO 01/32651; for example those described in Examples 2(a), 2(b) and 2(c) of WO 01/32651.
  • ZD1839 may be synthesised according to any of the known processes for making ZD1839.
  • ZD1839 may be made according to the processes described in WO 96/33980 (See Examples 1, 10 and 24-31). The foUowing tests were used to demonstrate the activity of ZD6474 in combination with ZD 1839.
  • mice Five days after implantation when tumours reached a mean volume of approximately 0.3 cm 3 , mice were treated with ZD6474 (6 mg/kg/administration), ZD1839 (50 mg/kg/administration), or a combination thereof, oraUy (p.o.) daUy for 15 days (day 0 - 14).
  • ZD6474, ZD1839 or the combination were dosed at O.lml/lOg body weight, as suspensions in 1% polysorbate 80 (i.e. a 1% (v/v) solution of polyoxyethylene (20) sorbitan mono-oleate in deionised water). Growth inhibition from the start of treatment was assessed by comparison of the differences in tumor volume between control and treated groups. A one-ta ed two-sample t-test was used to evaluate the significance of tumour growth inhibition.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor, which comprises the administration of ZD6474 in combination with ZD1839; to a pharmaceutical composition comprising ZD6474 and ZD1839; to a combination product comprising ZD6474 and ZD1839 for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and ZD1839; to the use of ZD6474 and ZD1839 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

Description

COMBINATION OF VEGF RECEPTOR YROSINE KINASE NHIBITORS FOR TREATMENT OF
CANCER
The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with ZD 1839; to a pharmaceutical composition comprising ZD6474 and ZD1839; to a combination product comprising ZD6474 and ZD1839 for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and ZD1839; to the use of ZD6474 and ZD1839 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warmblooded animal such as a human which is optionally being treated with ionising radiation.
Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1 : 27-31). Alteration of vascular permeability is thought to play a role in both normal and pathological physiological processes (CuBinan-Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324). Several polypeptides with in vitro endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (NEGF). By virtue of the restricted expression of its receptors, the growth factor activity of NEGF, in contrast to that of the FGFs, is relatively specific towards endothelial cells. Recent evidence indicates that NEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al, 1995, Breast Cancer Research and Treatment, 36:139-155) and vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264: 20017-20024). Antagonism of NEGF action by sequestration of NEGF with antibody can result in inhibition of tumour growth (Kim et al, 1993, Nature 362: 841-844). Receptor tyrosine kinases (RTKs) are important in the transmission of biochemical signals across the plasma membrane of cells. These transmembrane molecules characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which leads to phosphorylation of tyrosine residues on both the receptor and other intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, at least nineteen distinct RTK subfamilies, defined by amino acid sequence homology, have been identified. One of these subfamilies is presently comprised by the fms-like tyrosine kinase receptor, Flt-1, the kinase insert domain-containing receptor, KDR (also referred to as Flk-1), and another fms-like tyrosine kinase receptor, Flt-4. Two of these related RTKs, Flt-1 and KDR, have been shown to bind NEGF with high affinity (De Nries et al, 1992, Science 255: 989-991; Terman et al, 1992, Biochem. Biophys. Res. Comm. 1992, 187: 1579-1586). Binding of NEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins and calcium fluxes.
Quinazoline derivatives which are inhibitors of NEGF receptor tyrosine kinase are described in International Patent Applications Publication Νos. WO 98/13354 and WO 01/32651. In WO 98/13354 and WO 01/32651 compounds are described which possess activity against NEGF receptor tyrosine kinase (NEGF RTK) whilst possessing some activity against epidermal growth factor (EGF) receptor tyrosine kinase (EGF RTK). ZD6474 is 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-( 1 -methylpiperidin-4- ylmethoxy)quinazoline:
Figure imgf000003_0001
ZD6474 ZD6474 falls within the broad general disclosure of WO 98/13354 and is exemplified in WO 01/32651. ZD6474 is a potent inhibitor of NEGF RTK and also has some activity against EGF RTK. ZD6474 has been shown to elicit broad-spectrum anti-tumour activity in a range of models following once-daily oral administration (Wedge S.R., Ogilvie D.J., Dukes M. et al, Proc. Am Assoc. Cane. Res. 2001; 42: abstract 3126). In WO 98/13354 and WO 01/32651 it is stated that compounds of their inventions: "may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment."
WO 98/13354 and WO 01/32651 then go on to describe examples of such conjoint treatment including surgery, radiotherapy and various types of chemotherapeutic agent including inhibitors of growth factor function.
Nowhere in WO 98/13354 and WO 01/32651 does it suggest the combination of a compound of the invention and an epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of any disease state including cancer.
Nowhere in WO 98/13354 and WO 01/32651 is the specific combination of ZD6474 and ZD 1839 suggested.
Nowhere in WO 98/13354 and WO 01/32651 does it state that use of any compound of the invention therein with other treatments will produce surprisingly beneficial effects.
Unexpectedly and surprisingly we have now found that the particular compound ZD6474 used in combination with a particular selection from the broad description of combination therapies listed in WO 98/13354 and WO 01/32651, namely with ZD1839, produces significantly better effects than any one of ZD6474 and ZD1839 used alone. In particular, ZD6474 used in combination with ZD1839 produces significantly better effects on solid tumours than any one of ZD6474 and ZD1839 used alone.
ZD1839 is N-(3-cHoro-4-fluorophenyl)-7-methoxy-6-(3- mo hol opropoxy)quinazolm-4-amine:
Figure imgf000004_0001
ZD1839 ZD1839 is also known as gefitinib and is also known as Iressa™ (Trademark of AstraZeneca UK Limited) and it is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). ZD1839 is described in International Patent Application Publication No. WO 96/33980.
In recent years it has been discovered that certain growth factor tyrosine kinase enzymes are important in the transmission of biochemical signals which initiate cell replication. They are large proteins which span the cell membrane and possess an extracellular binding domain for growth factors, for example the epidermal growth factor receptor (EGER) which binds epidermal growth factor (EGF), and an intracellular portion which functions as a kinase to phosphorylate tyrosine a ino acids in proteins and hence to influence cell proliferation. EGFR is a member of the erbB family of receptor tyrosine kinases, which includes EGFR, erbB2, erbB3 and erbB4, and it is known that these receptor tyrosine kinases are frequently involved in driving the proliferation and survival of tumour cells (reviewed in Olayioye et al., EMBO J., 2000, 19, 3159). One mechanism by which this can be accomplished is by overexpression of the receptor at the protein level, generally as a result of gene amplification. This has been observed in many common human cancers (reviewed in Klapper et al., Adv. Cancer Res., 2000, 77, 25), such as breast cancer (Sainsbury et al., Brit. J. Cancer, 1988, 58, 458; Guerin et al., Oncogene Res., 1988, 3, 21; Slamon et al., Science, 1989, 244, 707; Khjn et al., Breast Cancer Res. Treat., 1994, 29, 73 and reviewed in Salomon et al., Crit. Rev. Oncol. Hematol., 1995, 19, 183), non-small cell lung cancers (NSCLCs) including adenocarcinomas (Cerny et al., Brit. J. Cancer, 1986, 54, 265; Reubi et al., Int. J. Cancer, 1990, 45, 269; Rusch et al., Cancer Research, 1993, 53, 2379; Brabender et al, Clin. Cancer Res., 2001, 7, 1850) as well as other cancers of the lung (Hendler et al., Cancer Cells, 1989, 7, 347; Ohsaki et al., Oncol. Rep., 2000, 7, 603), bladder cancer (Neal et al., Lancet, 1985, 366; Chow et al., Clin. Cancer Res., 2001, 7, 1957, Zhau et al., Mol Carcinog., 3, 254), oesophageal cancer (Mukaida et al., Cancer, 1991, 68, 142), gastrointestinal cancer such as colon, rectal or stomach cancer (Bolen et al., Oncogene Res., 1987, 1, 149; Kapitanovic et al., Gastroenterology, 2000, 112, 1103; Ross et al., Cancer Invest., 2001, 19, 554), cancer of the prostate (Visakorpi et al., Histochem J., 1992, 24, 481; Kumar et al., 2000, 32, 73; Scher et al., J. Natl. Cancer Inst., 2000, 92, 1866), leukaemia (Konaka et al., Cell, 1984, 37, 1035, Martin-Subero et al., Cancer Genet Cytogene , 2001, 127, 174), ovarian cancer (Hellstrom et al., Cancer Res., 2001, 61, 2420), head and neck cancer (Shiga et al, Head Neck, 2000, 22, 599) and pancreatic cancer (Ovotny et al., Neoplasma, 2001, 48, 188). It is widely believed that as a consequence of the dysfunctional regulation of one or more of these receptors many tumours become clinically more aggressive and this correlates with a poorer prognosis for the patient (Brabender et al, Clin. Cancer Res., 2001, 7, 1850; Ross et al, Cancer Investigation, 2001, 19, 554, Yu et al., Bioessays, 2000, 22.7, 673). In addition to these clinical findings, a wealth of pre-clinical information suggests that the erbB family of receptor tyrosine kinases are involved in cellular transformation. This includes the observations that many tumour cell lines overexpress one or more of the erbB receptors and that EGFR or erbB2 when transfected into non-tumour cells have the ability to transform these cells. In addition to this, a number of pre-clinical studies have demonstrated that anti-proliferative effects can be induced by knocking out one or more erbB activities by small molecule inhibitors, dominant negatives or inhibitory antibodies (reviewed in Mendelsohn et al., Oncogene, 2000, 19, 6550). Thus it has been recognised that inhibitors of these receptor tyrosine kinases should be of value as selective inhibitors of the proliferation of m-unmalian cancer cells (Yaish et al. Science, 1988, 242, 933, Kolibaba et al, Biochimica et Biophysica Acta, 1997, 133, F217-F248; Al-Obeidi et al, 2000, Oncogene, 19, 5690-5701; Mendelsohn et al, 2000, Oncogene, 19, 6550-6565). In addition to this pre-clinical data, the use of inhibitory antibodies against EGFR and erbB2 (c-225 and trastuzumab respectively) has proven to be beneficial in the clinic for the treatment of selected solid tumours (reviewed in Mendelsohn et al, 2000, Oncogene, 19, 6550-6565). It is believed that members of the erbB type receptor tyrosine kinase family may be implicated in a number of non-malignant proliferative disorders because amplification and/or activity of erbB receptor tyrosine kinases has been detected in psoriasis (Ben-Bassat, Curr. Pharm Des., 2000, 6, 933; Elder et al., Science, 1989, 243, 811), benign pro static hyperplasia (BPH) (Kumar et al., Int. Urol. Nephrol., 2000, 32,73), atherosclerosis and restenosis (Bokemeyer et al., Kidney Int., 2000, 58, 549). It is therefore expected that inhibitors of erbB type receptor tyrosine kinases will be useful in the treatment of these and other non-malignant disorders involving excessive cellular proliferation.
It is known from International Patent Application Publication No. WO 96/33980 that ZD1839 possesses EGF RTK inhibitory activity (J R Woodburn et al in Proc. Amer. Assoc. Cane. Res., 1997, 38, 633 and Pharmacol. Ther., 1999, 82, 241-250) and is an inhibitor of the proliferation of cancer tissue. It is stated in WO 96/33980 that compounds of the invention, which include ZD1839, may be given conjointly with other cancer therapies. It states therein "The anti-proliferative treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the quinazoline derivative of the invention, one or more other anti-tumour substances, for example cytotoxic or cytostatic anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine, vindesine and vinorelbine; tubulin disassembly inhibitors such as taxol; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; antimetabolites, for example 5-fluorouracil, tegafur, methotrexate, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European Patent Application No. 239362 such as N- { 5- [N-(3 ,4-dihydro-2-metiiyl-4-oxoquinazolin-6-y]methyl)-N- methylamino]-2-thenoyl}-L-glutamic acid; intercalating antibiotics, for example adriamycin, mitomycin and bleomycin; enzymes, for example asparaginase; topoisomerase inhibitors, for example etoposide and camptothecin; biological response modifiers, for example interferon; anti-hormones, for example antioestrogens such as tamoxifen, for example antiandrogens such as 4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)- propionanilide or, for example LHRH antagonists or LHRH agonists such as goserelin, leuprorelin or buserelin and hormone synthesis inhibitors, for example aromatase inhibitors such as those disclosed in European Patent Application No. 0296749, for example 2,2'-[5-(lH- 1,2,4- triazol-l-ylmethyl)-l,3-phenylene]bis(2-methylpropionitrile), and, for example, inhibitors of 5 -reductase such as 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-l-en-3-one."
Nowhere in WO 96/33980 does it suggest any combination of an EGF RTK inhibitor with a NEGF RTK inhibitor for the treatment of any disease state including cancer.
International Patent Application Publication No. WO 02/41882 describes, generally, combinations of agents wliich decrease NEGF activity and agents which decrease EGF activity. A study has been carried out exarmning co-administration of antibodies to KDR and EGFR (Shaheen, R.M., et al., Brit. J. Cancer, 2001, 85, 584-589).
Unexpectedly and surprisingly we have now found that the particular compound ZD6474 used in combination with the particular compound ZD1839, produces significantly better anti-tumour effects than each of ZD6474 and ZD 1839 used alone.
Anti-cancer effects of a method of treatment of the present invention include, but are not limited to, anti-tumour effects, the response rate, the time to disease progression and the survival rate. Anti-tumour effects of a method of treatment of the present invention include but are not limited to, inhibition of tumour growth, tumour growth delay, regression of tumour, shrinkage of tumour, increased time to regrowth of tumour on cessation of treatment, slowing of disease progression. It is expected that when a method of treatment of the present invention is administered to a warm-blooded animal such as a human, in need of treatment for cancer, with or without a solid tumour, said method of treatment will produce an effect, as measured by, for example, one or more of: the extent of the anti-tumour effect, the response rate, the time to disease progression and the survival rate.
According to the present invention there is provided a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises adrninistering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof.
According to a further aspect of the present invention there is provided a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warmblooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof; wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof; wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier. According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof; wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
According to a further aspect of the invention there is provided a pharmaceutical composition wliich comprises ZD6474 or a pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.
According to a further aspect of the present invention there is provided a combination product comprising ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof, for use in a method of treatment of a human or a mal body by therapy. According to a further aspect of the present invention there is provided a kit comprising ZD6474 or a pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt thereof.
According to a further aspect of the present invention there is provided a kit comprising: a) ZD6474 or a pharmaceutically acceptable salt thereof in a first unit dosage form; b) ZD1839 or a pharmaceutically acceptable salt thereof in a second unit dosage form; and c) container means for containing said first and second dosage forms. According to a further aspect of the present invention there is provided a kit comprising: a) ZD6474 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient or carrier, in a first unit dosage form; b) ZD1839 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient or carrier, in a second unit dosage form; and c) container means for containing said first and second dosage forms. According to a further aspect of the present invention there is provided the use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD 1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.
According to a further aspect of the present invention there is provided the use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD 1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti- cancer effect in a warm-blooded animal such as a human.
According to a further aspect of the present invention there is provided the use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti- tumour effect in a warm-blooded animal such as a human.
According to a further aspect of the present invention there is provided a therapeutic combination treatment comprising the administration of an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable excipient or carrier, and the simultaneous, sequential or separate administration of an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof; wherein ZD1839 may optionally be administered together with a pharmaceutically acceptable excipient or carrier, to a warm-blooded arώnal such as a human in need of such therapeutic treatment. Such therapeutic treatment includes an antiangiogenic and/or vascular permeability effect, an anti-cancer effect and an anti-tumour effect.
A combination treatment of the present invention as defined herein may be achieved by way of the simultaneous, sequential or separate administration of the individual components of said treatment. A combination treatment as defined herein may be applied as a sole therapy or may involve surgery or radiotherapy or an additional chemotherapeutic agent, in addition to a combination treatment of the invention.
Surgery may comprise the step of partial or complete tumour resection, prior to, during or after the administration of the combination treatment with ZD6474 described herein. Other chemotherapeutic agents for optional use with a combination treatment of the present invention include those described in WO 01/32651 which is incorporated herein by reference. Such chemotherapy may cover five main categories of therapeutic agent:
(i) other antiangiogenic agents including vascular targeting agents; (ϋ) cy to static agents;
(iii) biological response modifiers (for example interferon);
(iv) antibodies (for example edrecolomab); and
(v) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology. The administration of a triple combination of ZD6474, ZD 1839 and ionising radiation may produce effects, such as anti-tumour effects, greater than those achieved with any of ZD6474, ZD1839 and ionising radiation used alone, greater than those achieved with the combination of ZD6474 and ZD1839, greater than those achieved with the combination of ZD6474 and ionising radiation and greater than those achieved with the combination of ZD1839 and ionising radiation.
According to the present invention there is pro ided a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
According to a further aspect of the present invention there is provided a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm- blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation, wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation, wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation, wherein ZD6474 and ZD1839 may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.
According to a further aspect of the present invention there is provided the use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
According to a further aspect of the present invention there is provided the use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti- cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
According to a further aspect of the present invention there is provided the use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD 1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti- tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
According to a further aspect of the present invention there is provided a therapeutic combination treatment comprising the administration of an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable excipient or carrier, and the administration of an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable excipient or carrier and the administration of an effective amount of ionising radiation, to a warm-blooded animal such as a human in need of such therapeutic treatment wherein the ZD6474, ZD1839 and ionising radiation may be administered simultaneously, sequentially or separately and in any order.
A warm-blooded animal such as a human which is being treated with ionising radiation means a warm-blooded animal such as a human which is treated with ionising radiation before, after or at the same time as the administration of a medicament or combination treatment comprising ZD6474 and ZD1839. For example said ionising radiation may be given to said warm-blooded animal such as a human within the period of a week before to a week after the administration of a medicament or combination treatment comprising ZD6474 and ZD1839. This means that ZD6474, ZD1839 and ionising radiation may be administered separately or sequentially in any order, or may be administered simultaneously. The warm-blooded animal may experience the effect of each of ZD6474, ZD1839 and radiation simultaneously.
According to one aspect of the present invention the ionising radiation is administered before one of ZD6474 and ZD1839 or after one of ZD6474 and ZD1839.
According to one aspect of the present invention the ionising radiation is administered before both ZD6474 and ZD1839 or after both ZD6474 and ZD1839.
According to one aspect of the present invention ZD6474 is administered to a warmblooded animal after the animal has been treated with ionising radiation. In another aspect of the present invention ZD6474 and ZD1839 are dosed daily continuously for a longer period of time during which time ionising radiation is administered periodically, that is for a few days, for example 1, 2, 3, 4 or 5 days at a time.
According to another aspect of the present invention the effect of a method of treatment of the present invention is expected to be at least equivalent to the addition of the effects of each of the components of said treatment used alone, that is, of each of ZD6474 and ZD1839 or of each of ZD6474, ZD1839 and ionising radiation used alone.
According to another aspect of the present invention the effect of a method of treatment of the present invention is expected to be greater than the addition of the effects of each of the components of said treatment used alone, that is, of each of ZD6474 and ZD 1839 or of each of ZD6474, ZD1839 and ionising radiation, used alone.
According to another aspect of the present invention the effect of a method of treatment of the present invention is expected to be a synergistic effect.
It should also be appreciated that according to the present invention a combination treatment is defined as affording a synergistic effect if the effect is therapeutically superior, as measured by, for example, the extent of the response, the response rate, the time to disease progression or the survival period, to that achievable on dosing one or other of the components of the combination treatment at its conventional dose. For example, the effect of the combination treatment is synergistic if the effect is therapeutically superior to the effect achievable with ZD6474 or ZD1839 or ionising radiation alone. Further, the effect of the combination treatment is synergistic if a beneficial effect is obtained in a group of patients that does not respond (or responds poorly) to ZD6474 or ZD1839 or ionising radiation alone. In addition, the effect of the combination treatment is defined as affording a synergistic effect if one of the components is dosed at its conventional dose and the other component(s) is/are dosed at a reduced dose and the therapeutic effect, as measured by, for example, the extent of the response, the response rate, the time to disease progression or the survival period, is equivalent to that achievable on dosing conventional amounts of the components of the combination treatment. In particular, synergy is deemed to be present if the conventional dose of ZD6474 or ZD1839 or ionising radiation may be reduced without detriment to one or more of the extent of the response, the response rate, the time to disease progression and survival data, in particular without detriment to the duration of the response, but with fewer and/or less troublesome side-effects than those that occur when conventional doses of each component are used.
As stated above the combination treatments of the present invention as defined herein are of interest for their antiangiogenic and/or vascular permeability effects. Combination treatments of the invention are expected to be useful in the prophylaxis and treatment of a wide range of disease states where inappropriate angiogenesis occurs including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, lymphoedema, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation including macular degeneration. In particular such combination treatments of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More especially combination treatments of the present invention are expected to slow advantageously the growth of tumours in lung cancer, particularly non- small cell lung cancer (NSCLC). More particularly such combination treatments of the invention are expected to inhibit any form of cancer associated with NEGF including leukaemia, mulitple myeloma and lymphoma and also, for example, to inhibit the growth of those primary and recurrent solid tumours wliich are associated with NEGF, especially those tumours which are significantly dependent on NEGF for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin, particularly ΝSCLC.
In another aspect of the present invention ZD6474 and ZD1839, optionally with ionising radiation, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with EGF especially those tumours which are significantly dependent on EGF for their growth and spread. In another aspect of the present invention ZD6474 and ZD1839, optionally with ionising radiation, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with both NEGF and EGF especially those tumours which are significantly dependent on NEGF and EGF for their growth and spread.
The compositions described herein may be in a form suitable for oral administration, for example as a tablet or capsule, for nasal administration or administration by inhalation, for example as a powder or solution, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream, for rectal administration for example as a suppository or the route of administration may be by direct injection into the tumour or by regional delivery or by local delivery. In other embodiments of the present invention the ZD6474 of the combination treatment may be delivered endoscopicaUy, intratracheaUy, intralesionaUy, percutaneously, intravenously, subcutaneously, intraperitoneaUy or intratumouraUy. Preferably ZD6474 is administered oraUy. In general the compositions described herein may be prepared in a conventional manner using conventional excipients. The compositions of the present invention are advantageously presented in unit dosage form. ZD6474 wh normally be administered to a warm-blooded animal at a unit dose within the range 10-500mg per square metre body area of the animal, for example approximately 0.3- 15mg/kg in a human. A unit dose in the range, for example, 0.3-15mg/kg, preferably 0.5-5mg/kg is envisaged and this is normaUy a therapeuticaUy-effective dose. A unit dosage form such as a tablet or capsule wiU usuaUy contain, for example 25-500mg of active ingredient. Preferably a daUy dose in the range of 0.5-5mg/kg is employed.
For ZD1839, a conventional tablet formulation may be used for oral administration to humans containing 50 mg, 100 mg, 250 mg or 500 mg of active ingredient. Conveniently the daUy oral dose of ZD 1839 is, for example, in the range 25 to 750 mg, preferably in the range 50 to 600 mg, more preferably in the range 100 to 400mg. Radiotherapy may be administered according to the known practices in clinical radiotherapy. The dosages of ionising radiation wiU be those known for use in clinical radiotherapy. The radiation therapy used wiU include for example the use of γ-rays, X-rays, and/or the directed dehvery of radiation from radioisotopes. Other forms of DNA damaging factors are also included in the present invention such as microwaves and UV-irradiation. For example X-rays may be dosed in daily doses of 1.8-2.0Gy, 5 days a week for 5-6 weeks. NormaUy a total fractionated dose will he in the range 45-60Gy. Single larger doses, for example 5-10Gy may be administered as part of a course of radiotherapy. Single doses may be administered intraoperatively. Hyperfractionated radiotherapy may be used whereby small doses of X-rays are administered regularly over a period of time, for example O.lGy per hour over a number of days. Dosage ranges for radioisotopes vary widely, and depend on the half- life of the isotope, the strength and type of radiation emitted, and on the uptake by ceUs. As stated above the size of the dose of each therapy which is required for the therapeutic or prophylactic treatment of a particular disease state wiU necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. For example, it may be necessary or desirable to reduce the above-mentioned doses of the components of the combination treatments in order to reduce toxicity.
The present invention relates to combinations of ZD 1839 or a salt thereof with ZD6474 or with a salt of ZD6474. Salts of ZD 1839 for use in pharmaceutical compositions wiU be pharmaceuticaUy acceptable salts, but other salts may be useful in the production of ZD 1839 and its pharmaceuticaUy acceptable salts. Salts include, for example, an acid-addition salt of ZD1839, for example, a mono- or di-acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric, maleic, tartaric, furnaric, methanesulphonic or 4-toluenesulphonic acid.
Salts of ZD6474 for use in pharmaceutical compositions wiU be pharmaceuticaUy acceptable salts, but other salts may be useful in the production of ZD6474 and its pharmaceuticaUy acceptable salts. Such salts may be formed with an inorganic or organic base which affords a pharmaceuticaUy acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2- hydroxyethyl) amine.
ZD6474 may be synthesised according to any of the known processes for making ZD6474. For example ZD6474 may be made according to any of the processes described in WO 01/32651; for example those described in Examples 2(a), 2(b) and 2(c) of WO 01/32651.
ZD1839 may be synthesised according to any of the known processes for making ZD1839. For example ZD1839 may be made according to the processes described in WO 96/33980 (See Examples 1, 10 and 24-31). The foUowing tests were used to demonstrate the activity of ZD6474 in combination with ZD 1839. Human LoNo colon tumour xeno grafts in Nude mice
107 LoNo tumour ceUs in 0.1 ml of serum free Dulbecco's Modified Eagle's Medium (DMEM) were injected subcutaneously (s.c.) into the flank of each athymic (nu/nu genotype) mouse. Tumor volumes were assessed by bUateral Vernier caUper measurement and, taking length to be the longest diameter across the tumor and width the corresponding perpendicular, calculated using the formula (length x width) x the square root of (length x width) x (π/6). Five days after implantation when tumours reached a mean volume of approximately 0.3 cm3, mice were treated with ZD6474 (6 mg/kg/administration), ZD1839 (50 mg/kg/administration), or a combination thereof, oraUy (p.o.) daUy for 15 days (day 0 - 14). ZD6474, ZD1839 or the combination, were dosed at O.lml/lOg body weight, as suspensions in 1% polysorbate 80 (i.e. a 1% (v/v) solution of polyoxyethylene (20) sorbitan mono-oleate in deionised water). Growth inhibition from the start of treatment was assessed by comparison of the differences in tumor volume between control and treated groups. A one-ta ed two-sample t-test was used to evaluate the significance of tumour growth inhibition.
Table I
Figure imgf000018_0001
The combination of ZD6474 with ZD 1839 produced greater inhibition of tumour growth than each of ZD6474 and ZD1839 alone. The data is shown graphicaUy in Figure 1.
Human A431 vulval carcinoma tumour xeno grafts in Nude mice
5 x 106 A431 tumour ceUs in 0.1 ml of serum free Dulbecco's Modified Eagle's Medium (DMEM) were injected subcutaneously (s.c.) into the flank of each athymic (nu/nu genotype) mouse. Eleven days after inoculation tumours were excised and dissected to generate cubic tumour fragments of 0.5 - 1 mm3, which were implanted into further nude mice for a therapy experiment. Tumour volumes were assessed by bUateral Vernier caUper measurement and, taking length to be the longest diameter across the tumour and width the corresponding perpendicular, calculated using the formula (length x width) x the square root of (length x width) x (π/6). Twenty eight days after implantation when tumours reached a mean volume of 0.7cm3, mice were treated with ZD6474 (50 mg/kg/day), ZD1839 (50 mg/kg/day), or a combination thereof, oraUy (p.o.) for 31 days (day 28 - 59). ZD6474, ZD1839 or the combination, were dosed at O.lml/lOg body weight, as suspensions in 1% polysorbate 80 (i.e. a 1% (v/v) solution of polyoxyethylene (20) sorbitan mono-oleate in deionised water). Mhibition of tumour growth from the start of treatment was assessed on day 49 (the point at which control animals were removed from the experiment because of tumour burden) by comparison of the differences in tumor volume between control and treated groups. In addition, the number of tumour regressions foUowing 31 days of treatment was ascertained (tumour regression being evident if the tumour volume at day 59 was smaUer than the pre- treatment value on day 28).
Table I
Figure imgf000019_0001
The combination of ZD6474 with ZD1839 produced a greater inhibition of tumour growth than each of ZD6474 and ZD1839 alone at day 59 (P<0.001 versus ZD6474 alone, and P<0.009 versus ZD1839 alone; one-taUed t-test). In contrast to treatment with ZD6474 or ZD1839 alone, regression was induced in aU A431 vulval carcinoma xenografts treated with the combination of ZD6474 and ZD1839. The magnitude of tumour regression induced by the combination (calculated by comparing the pre- treatment tumour volume (day 28) with the volume foUowing 31 days of treatment (day 59)), reached 71 ± 3 % (mean ± SE) by the end of the experiment.
The data is shown graphicaUy in Figure 2.

Claims

1. A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceuticaUy acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceuticaUy acceptable salt thereof.
2. A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceuticaUy acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceuticaUy acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
3. A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceuticaUy acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceuticaUy acceptable salt thereof.
4. A method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceuticaUy acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceutically acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
5. A method for the treatment of a cancer involving a soUd tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceuticaUy acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceuticaUy acceptable salt thereof.
6. A method for the treatment of a cancer involving a soUd tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceuticaUy acceptable salt thereof, before, after or simultaneously with an effective amount of ZD 1839 or a pharmaceuticaUy acceptable salt thereof and before, after or simultaneously with an effective amount of ionising radiation.
7. A pharmaceutical composition which comprises ZD6474 or a pharmaceuticaUy acceptable salt thereof, and ZD1839 or a pharmaceuticaUy acceptable salt thereof, in association with a pharmaceuticaUy acceptable excipient or carrier.
8. A kit comprising ZD6474 or a pharmaceuticaUy acceptable salt thereof, and ZD1839 or a pharmaceuticaUy acceptable salt thereof.
9. Use of ZD6474 or a pharmaceuticaUy acceptable salt thereof and ZD1839 or a pharmaceuticaUy acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.
10. Use of ZD6474 or a pharmaceuticaUy acceptable salt thereof and ZD1839 or a pharmaceuticaUy acceptable salt tliereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
11. Use of ZD6474 or a pharmaceuticaUy acceptable salt thereof and ZD 1839 or a pharmaceuticaUy acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.
12. Use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceuticaUy acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
13. Use of ZD6474 or a pharmaceuticaUy acceptable salt thereof and ZD1839 or a pharmaceuticaUy acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.
14. Use of ZD6474 or a pharmaceuticaUy acceptable salt thereof and ZD 1839 or a pharmaceuticaUy acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
PCT/GB2003/003390 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer WO2004014426A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BR0313117-3A BR0313117A (en) 2002-08-09 2003-08-05 Method for producing a vascular and / or antiangiogenic permeability reducing effect in a warm-blooded animal such as a human, method for treating cancer in a warm-blooded animal such as a human, pharmaceutical composition, kit, and , use of zd6474 or a pharmaceutically acceptable salt thereof and zd1839 or a pharmaceutically acceptable salt thereof
EP03784248A EP1534338A1 (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
NZ537754A NZ537754A (en) 2002-08-09 2003-08-05 Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer
AU2003252976A AU2003252976B2 (en) 2002-08-09 2003-08-05 Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer
JP2004527018A JP2006500346A (en) 2002-08-09 2003-08-05 Combination of VEGF receptor tyrosine kinase inhibitors for the treatment of cancer
CA002495489A CA2495489A1 (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
US10/523,838 US20050245549A1 (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
MXPA05001457A MXPA05001457A (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer.
NO20050528A NO20050528L (en) 2002-08-09 2005-01-31 Combination of VEGF receptor tyrosine kinase inhibitors for the treatment of cancer
IL16662505A IL166625A0 (en) 2002-08-09 2005-02-01 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
US12/501,593 US20100130493A1 (en) 2002-08-09 2009-07-13 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218526.2A GB0218526D0 (en) 2002-08-09 2002-08-09 Combination therapy
GB0218526.2 2002-08-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/501,593 Continuation US20100130493A1 (en) 2002-08-09 2009-07-13 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Publications (1)

Publication Number Publication Date
WO2004014426A1 true WO2004014426A1 (en) 2004-02-19

Family

ID=9942013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003390 WO2004014426A1 (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Country Status (14)

Country Link
US (2) US20050245549A1 (en)
EP (1) EP1534338A1 (en)
JP (1) JP2006500346A (en)
KR (1) KR20050059060A (en)
CN (1) CN100556456C (en)
BR (1) BR0313117A (en)
CA (1) CA2495489A1 (en)
GB (1) GB0218526D0 (en)
IL (1) IL166625A0 (en)
MX (1) MXPA05001457A (en)
NO (1) NO20050528L (en)
NZ (1) NZ537754A (en)
WO (1) WO2004014426A1 (en)
ZA (1) ZA200501061B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113151A2 (en) * 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
US7462623B2 (en) 2002-11-04 2008-12-09 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
EP2053048A1 (en) 2005-09-30 2009-04-29 AstraZeneca AB Chemical in situ sulphonating process
US7829573B2 (en) 2000-04-05 2010-11-09 Astrazeneca Ab Therapeutic combinations of antihypertensive and antiangiogenics agents
RU2492864C2 (en) * 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Method of treating cancer carrying egfr mutations
US9040548B2 (en) 1999-11-05 2015-05-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DK1592423T3 (en) * 2003-02-13 2011-06-27 Astrazeneca Ab Combination therapy of ZD6474 with 5-FU and / or CPT-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
MXPA06000114A (en) * 2003-07-10 2006-04-27 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability.
BRPI0516052A (en) * 2004-09-27 2008-08-19 Astrazeneca Ab use of zd6474 or a pharmaceutically acceptable salt thereof and imatinib, pharmaceutical composition, kit, and method for producing an antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
DE602006020621D1 (en) * 2005-12-22 2011-04-21 Astrazeneca Ab COMBINATION OF ZD6474 AND PEMETREXED
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
US20100092466A1 (en) * 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE369894T1 (en) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh COMBINATION CONTAINING AN AGENT FOR REDUCING VEGF ACTIVITY AND AN AGENT FOR REDUCING AGENT EGF ACTIVITY
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
CA2482591A1 (en) * 2002-04-16 2003-10-30 Astrazeneca Ab Combination therapy for the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
KR20050056190A (en) * 2002-08-09 2005-06-14 아스트라제네카 아베 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
DK1592423T3 (en) * 2003-02-13 2011-06-27 Astrazeneca Ab Combination therapy of ZD6474 with 5-FU and / or CPT-11
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
MXPA06000114A (en) * 2003-07-10 2006-04-27 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability.
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
BRPI0516052A (en) * 2004-09-27 2008-08-19 Astrazeneca Ab use of zd6474 or a pharmaceutically acceptable salt thereof and imatinib, pharmaceutical composition, kit, and method for producing an antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
DE602006020621D1 (en) * 2005-12-22 2011-04-21 Astrazeneca Ab COMBINATION OF ZD6474 AND PEMETREXED

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR [KDR]-TKI), in a model of ZD1839 ('Iressa') resistance", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11-01), pages S60 - S61, XP004403633, ISSN: 0959-8049 *
CIARDIELLO F ET AL: "ANTITUMOR EFFECT AND POTENTIATION OF CYTOTOXIC DRUGS ACTIVITY IN HUMAN CANCER CELLS BY ZD-1839 (IRESSA), AN EPIDERMAL GROWTH FACTOR RECEPTOR-SELECTIVE TYROSINE KINASE INHIBITOR", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 6, no. 5, May 2000 (2000-05-01), pages 2053 - 2063, XP001009786, ISSN: 1078-0432 *
HENNEQUIN LAURENT F ET AL: "Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 6, 14 March 2002 (2002-03-14), March 14, 2002, pages 1300 - 1312, XP002256124, ISSN: 0022-2623 *
HOLDEN S ET AL: "Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study.", EUROPEAN JOURNAL OF CANCER, vol. 37, no. Supplement 6, October 2001 (2001-10-01), 11th European Cancer Conference;Lisbon, Portugal; October 21-25, 2001, October, 2001, pages S73, XP002256123, ISSN: 0959-8049 *
MAGNÉ N ET AL: "Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer", BRITISH JOURNAL OF CANCER 04 MAR 2002 UNITED KINGDOM, vol. 86, no. 5, 4 March 2002 (2002-03-04), pages 819 - 827, XP002256122, ISSN: 0007-0920 *
MANLEY PAUL W ET AL: "Therapies directed at vascular endothelial growth factor.", EXPERT OPINION ON INVESTIGATIONAL DRUGS. ENGLAND DEC 2002, vol. 11, no. 12, December 2002 (2002-12-01), pages 1715 - 1736, XP002256125, ISSN: 1354-3784 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457664B2 (en) 1999-11-05 2019-10-29 Genzyme Corporation Quinazoline derivatives as VEGF inhibitors
US9040548B2 (en) 1999-11-05 2015-05-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US7829573B2 (en) 2000-04-05 2010-11-09 Astrazeneca Ab Therapeutic combinations of antihypertensive and antiangiogenics agents
US7462623B2 (en) 2002-11-04 2008-12-09 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
WO2006113151A3 (en) * 2005-04-14 2007-01-11 Wyeth Corp Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
WO2006113151A2 (en) * 2005-04-14 2006-10-26 Wyeth Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
WO2007014335A3 (en) * 2005-07-27 2007-04-12 Univ Texas Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
JP2009502960A (en) * 2005-07-27 2009-01-29 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム Combination comprising gemcitabine and tyrosine kinase inhibitor for the treatment of pancreatic cancer
EP2053048A1 (en) 2005-09-30 2009-04-29 AstraZeneca AB Chemical in situ sulphonating process
US9539258B2 (en) 2005-11-11 2017-01-10 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
RU2492864C2 (en) * 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Method of treating cancer carrying egfr mutations
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US10004743B2 (en) 2009-07-06 2018-06-26 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors

Also Published As

Publication number Publication date
IL166625A0 (en) 2006-01-15
EP1534338A1 (en) 2005-06-01
CN1674938A (en) 2005-09-28
ZA200501061B (en) 2007-01-31
NO20050528L (en) 2005-05-03
KR20050059060A (en) 2005-06-17
BR0313117A (en) 2005-07-05
US20050245549A1 (en) 2005-11-03
CA2495489A1 (en) 2004-02-19
JP2006500346A (en) 2006-01-05
NZ537754A (en) 2008-02-29
GB0218526D0 (en) 2002-09-18
MXPA05001457A (en) 2005-06-06
AU2003252976A1 (en) 2004-02-25
CN100556456C (en) 2009-11-04
US20100130493A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
US20100130493A1 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
US20100179142A1 (en) Cancer Combination Therapy Comprising AZD2171 and ZD1839
NZ544458A (en) Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
NZ568811A (en) Combination of ZD6474 and pemetrexed for treating cancer and the like
EP1496909B1 (en) Combination therapy for the treatment of cancer
WO2007071970A2 (en) Combination of azd2171 and pemetrexed
ZA200607555B (en) Combination therapy
EP1729807B1 (en) Combination therapy with azd-2171
US20090176731A1 (en) Combination therapy of cancer with azd2171 and gemcitabine
AU2003252976B2 (en) Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 537754

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003252976

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003784248

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 166625

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2495489

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001457

Country of ref document: MX

Ref document number: 200501061

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020057002187

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038191105

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10523838

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004527018

Country of ref document: JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003784248

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057002187

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2003252976

Country of ref document: AU